Jan 2, 2019 · 28m · a16z
a16z Podcast | The Science Of Extending Life
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of the a16z Podcast, host Hannah and an expert panel explore geroscience and the revolution in longevity medicine. They discuss shifting healthcare focus from lifespan to health span, key biological aging mechanisms, computational drug discovery, regulatory pathways, and the socioeconomic impacts of extended human vitality.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 2.7 Guest teaching 3.3 Guest disagreement 1.3 The host pushing back 1.7
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 25:24 Vijay Pande reframe on retirement and productivity
Vijay directly counters Hannah's concern about resource consumption by arguing that added years represent 40 productive expert years rather than added burden.
Hardest push from the host ▶ 25:08 Hannah pushes back on resource constraints of living longerHannah refuses a purely positive framing of life extension, raising the concrete counter-argument of planetary resource and food supply strains.
Biggest teaching moment ▶ 16:13 Dr. Rando corrects host's assumption about metformin dataDr. Rando explicitly corrects Hannah when she assumes metformin epidemiological data exists for healthy individuals, explaining that non-diabetics are not prescribed the drug.
The host holds their own ▶ 25:08 Hannah introduces demographic resource strain perspectiveHannah demonstrates broader societal perspective by challenging the assumption that extending human life by 40 years is purely beneficial without economic trade-offs.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Distinguishing Lifespan Extension from Health Span Extension | 2 | 3 | 1 | 1 | The host asks open conversational questions framing the basic distinction between lifespan and healthspan. Dr. Rando and Kristen Fortney explain the shift from invertebrate models to human biological age markers without conflict. | |
| Biological Mechanisms: Parabiosis, Young Blood, and Senolytics | 2 | 3 | 1 | 1 | Hannah brings up historical context regarding young blood myths, while the guests present scientific findings on parabiosis and senolytics. The tone remains collaborative with light conversational banter. | |
| Data Science, Biobanks, and Accelerated Drug Discovery | 2 | 4 | 0 | 1 | Kristen Fortney educates the listeners and host on how European biobanks with longitudinal health records accelerate aging research compared to traditional mouse trials. The host asks standard clarifying prompts. | |
| Commercialization Challenges and FDA Regulatory Pathways | 3 | 4 | 2 | 2 | When Hannah assumes observational metformin data exists for non-diabetic humans, Dr. Rando clarifies that healthy people do not take metformin so no such data exists. Hannah adjusts quickly as the discussion shifts to FDA disease indications. | |
| Therapeutic Delivery Modalities and Socioeconomic Equity | 3 | 3 | 1 | 2 | Hannah prompts a discussion on socioeconomic equity and whether therapies will initially be reserved for the wealthy. Guests outline how patent expirations and government public health interests balance delivery models. | |
| Societal Demographics, Workforces, and Quality of Life | 4 | 3 | 3 | 3 | Hannah challenges the unmixed optimism of extended lifespan by citing population resource strain and food supply issues. Vijay Pande counters that extended healthspan expands productive working years rather than mere end-of-life dependency. |
Statements from this episode (14)
Rando: Science focuses on extending health span, not just life span
“There's a big discrepancy between the notion of life extension and the notion of health span extension.”
Pande: Life extension is the ultimate endpoint for improving healthcare
“I think about life extension very much as the ultimate endpoint for improving healthcare and why we're doing this in the first place.”
Rando: Biological age biomarkers will enormously accelerate longevity research
“And I think, you know, the idea of having biomarkers is going to accelerate this field enormously.”
Rando: Infusing young blood into old animals reverses some aging phenotypes
“What we really know these days is that it does seem that if you infuse Components of a blood from a young animal into an old animal. It actually can revert some of the aging phenotypes from an old state to a younger state, which is something quite different be…”
Fortney: Clearing senescent cells in mice boosted lifespan by 30 percent
“And they showed that if you killed senescent cells in a mouse, you could boost lifespan by 30%.”
Fortney: NIA tested 30 lifespan drugs compared to 110,000 for cancer
“The National Cancer Institute, the total number of drugs they've given to mice to see if they cure mouse cancer is over a 110,000. The number of drugs that the National Institute on Aging has given to mice to see if they live longer is 30.”
Fortney: Rapamycin extended middle-aged mouse lifespan by 30 percent
“Even though they've only tested 30, there's already been one success rapamycin that came out of that, which is a very exciting discovery. Basically, the first molecule that came out of this large-scale program, they started to feed it to mice at middle age, an…”
Rando: The FDA will not approve drugs to treat healthy individuals
“There's no way right now that any drug is going to be approved for treatment of healthy people.”
Fortney: Statins function as anti-aging drugs in current medical practice
“Statins, which basically are an aging drug now. The indication is, oh, you're over 40, have some statins.”
Fortney: Longevity startups should target small initial indications to avoid huge trials
“Even if we came up with a drug that we thought slowed aging tomorrow, and I thought it would be wonderful for diabetes, I probably wouldn't want to go out and pay for a diabetes trial, right? That's a very competitive space. You need a huge, expensive trial wi…”
Rando: Young plasma clinical trial underway for early-onset Alzheimer's patients
“The company based on the kind of this work of the blood transfusions is currently conducting a trial of delivering Plasma from young individuals to patients with early onset Alzheimer's disease.”
Fortney: Small molecule longevity drugs will likely emerge first
“I guess I'm expecting small molecules to come first because that's what pharma is used to. You know, that's what the, we have all the models to make that work. And the space of chemicals has been so unexplored. So I think there are going to be other repomycins…”